Clinical trials: Apixaban
Atrial Fibrillation
Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S
The overall objective of this proposal is to execute a real-world database analysis to evaluate hospital readmissions among hospitalized nonvalvular atrial fibrillation (NVAF) patients in the U.S.
- Trial name
- NCT02769078
- Testing
- dabigatran, rivaroxaban, apixaban
- Volunteers
- 14,201 people
- Sponsor
- Bristol-Myers Squibb
Pulmonary Embolism Acute, Venous Thromboembolism (VTE)
Bleeding Risk With Apixaban Versus Rivaroxaban in Acute Pulmonary Embolism
This prospective, open-label, randomized controlled trial will compare clinically relevant bleeding during the first three months of treatment with apixaban versus rivaroxaban in adults with acute pulmonary embolism (PE) in a…
- Trial name
- APIX-PE (Apixa (NCT07774273)
- Testing
- Drug: Apixaban, Drug: Rivaroxaban
- Where
- Pakistan
- Volunteers
- 540 people
- Sponsor
- Combined military hospital lahore
Multiple Myeloma, Total Knee Replacement
Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma
Patients with multiple myeloma (MM) are at high risk of venous thromboembolism (VTE) and these patients require adequate thromboprophylaxis.
- Trial name
- ProApix (NCT06474182)
- Testing
- Blood sampling, Apixaban
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Venous Thromboembolism, Deep Venous Thrombosis
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Trial name
- ASTER (NCT05171049)
- Testing
- Abelacimab, Apixaban
- Where
- 209 sites in United States, Australia and 19 more
- Volunteers
- 1,150 people
- Sponsor
- Anthos Therapeutics, Inc.
Deep Venous Thrombosis, Pulmonary Embolism
The DARE Warfarin CER Study
Approximately half a million Americans annually experience venous thromboembolic disease, including deep venous thrombosis (DVT) and pulmonary embolism (PE).
- Trial name
- NCT03271450
- Testing
- Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days)
- Where
- United States
- Volunteers
- 416,000 people
- Sponsor
- Brigham and Women's Hospital
Left Ventricular Thrombus, Acute Myocardial Infarction
Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction
The optimal anticoagulant for the treatment of left ventricular (LV) thrombus following acute myocardial infarction (AMI) is unclear.
- Trial name
- RESOLVE-AMI (NCT06515730)
- Testing
- Apixaban, Warfarin
- Where
- 16 sites in Sweden
- Volunteers
- 212 people
- Sponsor
- Karolinska Institutet
LVAD (Left Ventricular Assist Device) Thrombosis, Heart Failure
SWITCH: Apixaban vs Vitamin K in HM3
This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced…
- Conditions
- LVAD (Left Ventricular Assist Device) Thrombosis, Heart Failure, Bleeding, Thrombosis; Artery
- Trial name
- NCT07471139
- Testing
- Warfarin, Apixaban
- Volunteers
- 460 people
- Sponsor
- Columbia University
Venous Thromboembolism (VTE)
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery.
- Trial name
- ROXI-APEX (NCT07015905)
- Testing
- REGN7508, Apixaban, Enoxaparin
- Where
- 47 sites in United States, Bulgaria and 6 more
- Volunteers
- 2,000 people
- Sponsor
- Regeneron Pharmaceuticals
Expanded Access for Apixaban
This is an expanded access designed to provide access to apixaban for eligible participants.
- Trial name
- NCT05187286
- Testing
- Apixaban
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Novel Oral Anticoagulants, NOACs
Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants
It is general that there are many factors for individual differences of drugs in clinical application, of which genetic factors accounted for more than 20%.
- Conditions
- Novel Oral Anticoagulants, NOACs, Rivaroxaban, Apixaban
- Trial name
- NCT03161496
- Testing
- detection of genotype
- Where
- 17 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Cui Yimin
Ischemic Stroke, Transient Ischemic Attack
Eliquis Acute Stroke Safety Evaluation
Study Design: This is an investigator-initiated prospective, open label, single arm phase IV study. Patients with documented non-valvular atrial fibrillation (AF) with acute TIA (defined as acute focal neurological deficits, with…
- Conditions
- Ischemic Stroke, Transient Ischemic Attack, Atrial Fibrillation
- Trial name
- EASSE (NCT04435418)
- Testing
- Apixaban
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of Alberta
Coagulation Disorder, Non Valvular Atrial Fibrillation
Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban
Apixaban is a potent, oral, selective reversible direct inhibitor of factor Xa with a favorable efficacy and safety profile in the prevention of non valvular (NV) atrial fibrillation (AF).
- Trial name
- ECAN (NCT03136510)
- Testing
- Apixaban 5 mg
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Hopital Lariboisière
Non-valvular Atrial Fibrillation
Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
The study purpose is to assess the impact of an educational program on patient adherence in patients taking Apixaban for SPAF at 24 weeks
- Trial name
- AEGEAN (NCT01884350)
- Testing
- Apixaban
- Where
- 220 sites in Belgium, France and 5 more
- Volunteers
- 1,217 people
- Sponsor
- Bristol-Myers Squibb
Acute Coronary Syndrome
Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation
Investigating Synergistic Effects of Apixaban with Dual Anti-Platelet Therapy (DAPT) in Lowering Platelet Reactivity and Thrombin Generation
- Trial name
- SEARCH (NCT03746782)
- Testing
- Flow Cytrometry; Thrombin Generation Assay
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CirQuest Labs, LLC
Atrial Fibrillation
Apixaban Dose Reduction in Patients With Elevated Drug Levels
Apixaban is an anticoagulant which is increasingly being used to prevent stroke in atrial fibrillation (AF). Phase III clinical trials have demonstrated that apixaban is efficacious and safe for the overall AF population…
- Trial name
- ADREL (NCT02809469)
- Testing
- apixaban dose reduction
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Hamilton Health Sciences Corporation
Healthy
Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT
This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with apixaban measuring clotting times using Whole Blood…
- Trial name
- NCT03288454
- Testing
- Ciraparantag, Apixaban
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Cancer Patients, Central Venous Catheter Thrombosis
Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in Cancer Patients
Cancer patients with Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) will be treated with Low Molecular Weight Heparin (LMWH) and apixaban. Study duration is 12 weeks.
- Conditions
- Cancer Patients, Central Venous Catheter Thrombosis, Upper Extremity Thrombosis
- Trial name
- NCT03100071
- Testing
- Apixaban
- Where
- 2 sites in Canada
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Michael Kovacs
Venous Thromboembolism
Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer
Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study
- Trial name
- CARAVAGGIO (NCT03045406)
- Testing
- Apixaban, Dalteparin
- Where
- 127 sites in United States, Belgium and 9 more
- Volunteers
- 1,170 people
- Sponsor
- Fadoi Foundation, Italy
Deep-Vein Thrombosis
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or…
- Trial name
- NCT00252005
- Testing
- Apixaban
- Where
- 72 sites in United States, Australia and 9 more
- Volunteers
- 520 people
- Sponsor
- Bristol-Myers Squibb
Pancreas Cancer, DVT
Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy
Study investigators will examine the absorption characteristics of apixaban, a direct-acting oral anticoagulation, in patients who have underwent a particular kind of surgery (pancreaticoduodenectomy) which involves resection of…
- Conditions
- Pancreas Cancer, DVT, Pulmonary Embolism
- Trial name
- PAP-UP (NCT04191928)
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Thomas Jefferson University